patent.fyi
Applications  /  US 2026/0355255
United States Patent Application Publication

US 2026/0355255 A1

Published
Nov 12, 2026
Filed
Jul 9, 2026
Earliest date on the face
Apr 24, 2015
Classification
A61K 35/38
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Open tray inside chamber

What ifWhat if the sample goes into an open tray inside an anaerobic chamber?
Claim language“an oxygen-tight collecting device”

An open stainless steel tray receives the sample through the chamber transfer port. The chamber atmosphere provides oxygen control while the tray holds the sample for mixing.

1.3Sugar based mixing liquid

What ifWhat if a sugar solution with no added salt provides the mixing liquid?
Claim language“saline aqueous solution”

Purified water and a dissolved sugar form the liquid carrier. The sugar concentration sets the carrier osmolality, and a paddle disperses the sample through the liquid.

1.3Pectin provides suspension viscosity

What ifWhat if dissolved pectin provides the viscosity needed to keep solids suspended?
Claim language“at least one maltodextrin”

High-methoxyl pectin hydrates in the mixing liquid before the sample enters. The hydrated polymer raises viscosity and slows the settling of suspended particles.

1.3Dry ingredients hydrate directly

What ifWhat if preweighed dry ingredients disperse directly in the moisture already present in the sample?
Claim language“mixing the sample obtained in b) with at least one saline aqueous solution”

A balance meters soluble ingredients into a moist sample as dry powders. A paddle mixer distributes the powders while water already in the sample dissolves them to form a paste.

1.4Gravity settling removes debris

What ifWhat if coarse solids settle by gravity before the upper suspension is withdrawn?
Claim language“filtering the mixture”

A conical vessel collects dense particles at its base while it stands upright. A wide-bore transfer tube draws the upper suspension from above the settled layer.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Frozen samples from anaerobic digesters

A sampling port on a wastewater digester feeds a gas-tight vessel for archiving sludge microbiota. A closed transfer line carries sludge to an oxygen-tight mixing vessel containing deoxygenated saline, cryoprotectant and maltodextrin. The slurry passes through a coarse screen into sealed vials for frozen storage.

Component substitution

Gravity settling for coarse solids removal

A sealed settling vessel with a conical base and a side outlet replaces the filter. The mixed suspension enters the vessel through a gas-tight inlet and stands until coarse solids collect in the base. A closed line draws the suspension from the side outlet above the settled layer and transfers it to containers for freezing.

Parameter or scale variation

Small aliquots in a standardized rack

A sealed manifold dispenses 1 mL of mixed suspension into each of twenty-four 2 mL screw-cap cryovials. The vials are filled and capped in an anaerobic enclosure, then held upright in a single-layer rack with 5 mm gaps between adjacent vials. The loaded rack enters a freezer set to −80 °C.

Combination with existing systems

Preparation inside an anaerobic glovebox

An anaerobic glovebox with a purgeable transfer chamber houses a sealed mixing vessel, a dispensing pump and a vial rack. The oxygen-tight collection device passes through the transfer chamber and opens inside the glovebox for mixing and dispensing. The vials are capped inside the glovebox and remain sealed during transfer to a freezer.

Automated or data-driven variant

Oxygen interlock for closed liquid transfer

Optical dissolved oxygen sensor spots sit inside the saline reservoir and the receiving vessel, where external readers measure them through transparent windows. A controller opens the transfer valves and starts the pump when both readings meet the configured oxygen limit. If either reading crosses the limit during transfer, the controller stops the pump, closes the valves and records the event.

Gravimetric dosing of the saline mixture

A sealed mixing vessel rests on a load cell and connects by closed tubing to a reservoir of prepared saline solution. A controller records the vessel mass before and after sample addition and calculates the solution dose from the net sample mass and a configured mass ratio. The controller stops the dosing pump at the target mass and starts the mixer before the suspension is dispensed into storage vials.

Specific version of a part

Single stool subsample

A disposable polypropylene scoop transfers one portion of freshly passed stool into the collection vessel. The difference between the empty and filled vessel masses gives the sample mass.

Crimp sealed glass vial

A borosilicate glass vial receives the sample in an anaerobic chamber. An aluminum crimp compresses a butyl rubber stopper against the vial rim to seal the opening.

Stainless steel mesh filtration

A stainless steel mesh with 0.5 mm openings sits between a feed cup and a receiving vessel. The suspension drains through the openings, and coarse fibers collect on the mesh.

Mechanical storage at −80 °C

Sealed aliquots prepared in an anaerobic chamber sit upright in a rack inside a mechanical freezer set to −80 °C. A temperature probe beside the rack records the storage temperature.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2012/0122071 A1
Published
May 17, 2012
Filed
Jun 11, 2010
Class
A01N 1/02
Document BUS 2013/0195804 A1
Published
Aug 1, 2013
Filed
Aug 4, 2011
Class
A61K 35/74
Claim 1
Document A
Document B
1.1a) taking at least one sample of faecal microbiota from the donor subject,
In alternative embodiments, the invention provides a process for preparing fecal flora (e.g., an entire (or substantially entire) microbiota) for transplantation, first comprising a collection from one or more healthy (e.g., screened) donor(s).
B · US 2013/0195804 A1 · ¶ 142
1.2b) placing said sample obtained in a) in an oxygen-tight collecting device,
In alternative embodiments, a fresh stool is transported via a stool collection device of the invention, which in one embodiment comprises a suitably oxygen free (or substantially oxygen free) appropriate container.
B · US 2013/0195804 A1 · ¶ 142
1.3c) mixing the sample obtained in b) with at least one saline aqueous solution comprising 15% by weight relative to the total volume of solution of at least one cryoprotectant selected from the group consisting of polyols, di- to pentasaccharides, DMSO and mixtures thereof, and 5% by weight relative to the total volume of solution of at least one maltodextrin to form a mixture,
A method of processing allograft skin for transplantation comprising: i) mixing dimethyl sulfoxide, an animal cell culture medium and fetal bovine serum; ii) dissolving sucrose in the solution to obtain a cryoprotectant; iii) penetrating the cryoprotectant into a separated skin; and iv) freezing the cryoprotectant-penetrated skin in a controlled rate freezer.
A · US 2012/0122071 A1 · claim 1
(g) the delivery vehicle, formulation, composition, pharmaceutical preparation, product of manufacture, container or device of any of (a) to (f), wherein a stabilizing agent or a glycerol is added to, or mixed into, the entire or substantially entire microbiota, the treated or untreated fecal flora sample, the complete or partial fecal flora sample, the fecal flora substantially or completely purified of non-fecal floral fecal material or the partially, substantially or compl
B · US 2013/0195804 A1 · claim 1
1.4d) optionally, filtering the mixture obtained in c), and
(h) the delivery vehicle, formulation, pharmaceutical preparation, product of manufacture, container or device of any of (a) to (g), wherein the fecal sample is treated such that the fecal flora is separated from rough particulate matter in the fecal sample by: homogenizing, centrifuging and/or filtering a rough particulate matter or a non-floral matter of the fecal material, or by plasmapheresis, centrifugation, centrifuge, column chromatography (e.g., affinity chromatograph
B · US 2013/0195804 A1 · ¶ 44
1.5e) storing the mixture obtained in c) or d) by freezing at a temperature between −15 °C and −100 °C, steps b) to e) being carried out under anaerobiosis.
As a result, if latent heat of fusion is not controlled by an excessive freezing rate of 10° C. per minute due to rapid freezing from the region in which latent heat of fusion is generated at freezing to −80° C. which is the temperature where the movement of water molecules stops, the skin tissue may be damaged by the formation of ice crystals.
A · US 2012/0122071 A1 · ¶ 17

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, the above method has a problem wherein treatment duration is long since cell viability is low.
A · US 2012/0122071 A1 · ¶ 5
Therefore, the technical problem to be solved in the present invention is the provision of a new method of processing allograft skin for transplantation which can efficiently increase cell viability and minimize change of biological properties compared with the conventional glycerol preservation method.
A · US 2012/0122071 A1 · ¶ 6
In alternative embodiments, compositions, devices and methods of the invention can be used for any gastric, gastrointestinal and or colonic treatment or lavage.
B · US 2013/0195804 A1 · ¶ 1
For example, after antibiotic therapy some of the families of the bacteria can be suppressed or eradicated and infectious agents such as Clostridium difficile and other pathogens can lodge and become passengers within the human flora.
B · US 2013/0195804 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355255 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355255/, SHA-256 79f5c5d0072207b926b997a53e19a1d99658de56c8d0d96229ab21c1fa9d2072
First published
Permanent addresshttps://patent.fyi/US20260355255/
Content fingerprint (SHA-256)79f5c5d0072207b926b997a53e19a1d99658de56c8d0d96229ab21c1fa9d2072
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi